Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2004

View Archived Issues

CTCE-0214 enters phase I studies for stem cell mobilization

RUP3 receptor as a target for diabetes and obesity

New oxytocin antagonists identified by ARS team

Novel NOS inhibitors prepared and tested at Altana

BMS claims new IKK inhibitors and their use in inflammatory and immune disorders

Chugai presents novel benzothiophene-based FTase inhibitors

Teijin scientists design novel MAPKAP-K2 inhibitors

New glucokinase activators emerge from Banyu R&D

Extension and expansion of Arena/Merck & Co. cardiovascular collaboration

New head-to-head phase III study of MedImmune CAIV-T and TIV flu vaccines

Immunomedics plans registration trials of epratuzumab in lupus

OraSure Technologies launches OraQuick Advance Rapid HIV-1/2 Antibody Test

Lundbeck files for new Alzheimer's indication for Ebixa in Europe

U.S. clinical development begins for smallpox vaccine candidate LC16m8

Positive phase II results for Corus-1020

Enrollment begins in INITIATE plus study of NovoLog Mix 70/30

Norak Biosciences and Curis sign research agreement

Orphan drug designation for 17-AAG in multiple myeloma

Nobex and Biocon to develop oral insulin product for diabetes

Formal animal toxicology study successfully completed for ACP-SL017

Avastin receives positive opinion in Europe for metastatic colorectal cancer

Gilead Sciences discontinues development of GS-9005 and GS-7340

Treatment under way in TheraSight trial

Long-term study shows Adderall XR is effective in adolescents with ADHD

Rotigotine prevents neuronal degeneration in a mouse model of PD

Therapeutic benefits of topical bimosiamose in psoriasis vulgaris

Sertraline plus sildenafil improve sexual activity of patients with premature ejaculation

New data on the pharmacokinetics and effects of topical testosterone in women

Novel antidepressant may improve side effect profile of selective serotonin reuptake inhibitors

New adenine derivative shows antidepressant-like effects in vivo

Dual opioid receptor agonist JNJ-10335572 shows good activity in in vivo GI assays

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...